About Us

---

Lisa Pan, M.D., F.A.P.A.    Founder, Chair

  Over the past 20 years, Dr. Pan has investigated the neurobiology of suicide attempt and treatment refractory depression in adolescents and young adults, utilizing cutting-edge, clinically-validated methods in functional neuroimaging and metabolomics to characterize suicidal behavior. Dr. Pan is board certified in Psychiatry and Neurology, with subspecialty certification in Child and Adolescent Psychiatry and has over a decade of work with teens and adults at risk for suicide. Among her many honors and awards, she received a Department of Defense  National Security Council Education Program Scholarship, was named an  AACAP Presidential Scholar, received an American Foundation for Suicide Prevention Young Investigator Grant, an NIH K23 Mentored Patient-Oriented Career Development Award, and a NARSAD Young Investigator Award from the Brain and Behavior Research Foundation. She is CEO/CMO of New Hope Molecular, LLC and maintains an active clinical practice in Mt. Lebanon, PA.       

Ian Magazine, M.B.A.   Board of Directors

Mr. Magazine is a Wall Street Investment Banker turned Entrepreneur, who has raised over $100M in equity financings. He is a seasoned technology executive whose career has spanned a broad set of technology innovations – from Life Sciences, IT, Robotics, and Telecom. He has built new businesses, identified highly profitable investments, and forged high-value partnerships resulting in well over a billion dollars of value creation. Business Development / Strategic Planning / Corporate Finance / Business Operations / Investor & Banking Relations / Mergers and Acquisitions / Re-engineering Business Processes / Due Diligence & Integration / Growth & Expansion  Forecasting & Budgeting / Organizational Leadership & Team Building. 

David Finegold, M.D.   Director of Education

  Dr. Finegold is an endocrinologist and biochemical geneticist. He is a faculty member in the Department of Human Genetics at University of Pittsburgh, where his research focuses on lymphatic vascular biology and genetic variation underly

ing primary and secondary lymphedema. Dr. Finegold is certified by the American Board of Pediatrics, the American Board of Pediatric Endocrinology, and the American Board of Medical Genetics (Biochemical Genetics). He is the co-principal investigator for the Pittsburgh Lymphedema Family Study, which aims to identify genes responsible for primary lymphedema as well as a co-investigator in Dr. Massimo Trucco's studies to rescue newly diagnosed patients with type I diabetes mellitus. He also advises two analytical chemistry groups developing novel biomolecular sensors and a chemical engineering sensing and modeling group. Prior to the founding of New Hope Molecular, he advised and served as a geneticist for Dr. Lisa Pan's suicide research group.   

David Peters, Ph.D.  Director of Research, Board of Directors Associate Professor, Department of Obstetrics, Gynecology & Reproductive Sciences. Dr. Peters has a long history of productivity in translational genomics and considerable experience of using massively-parallel and sequencing-based methods to characterize human disease mechanisms, develop novel diagnostic approaches and improve healthcare outcomes. He developed a method for the non-invasive prenatal detection of fetal aneuploidy via the shotgun sequencing analysis of DNA from maternal plasma obtained in early gestation. He was the first to demonstrate that certain variants of a polymorphic allele were functionally associated with aneurysm pathogenesis. Specifically, that polymorphisms in the MMP9 gene are commonly associated with intracranial aneurysms and that these variants directly affect MMP9 promoter function. He developed a patent with Dr. Pan for computational filtering of methylated sequence data for modeling in cerebrospinal fluid. 

Patricia Dobosh, Ph.D.   Director of Patient Advocacy 

Dr. Dobosh is a licensed Clinical Psychologist who has been practicing for the last 20 years. She specializes in Behavioral Medicine and Cognitive-Behavioral Therapy. Dr. Dobosh is trained in Dialectical Behavior Therapy in addition to other empirically-validated treatments. Furthermore, she is an expert psychometrician with considerable experience in making differential diagnoses and identifying underlying and complicated clinical concerns. Dr. Dobosh is a graduate of Gallaudet University in Washington, District of Columbia and completed her clinical training at the Louis Stokes Department of Veterans Affairs Medical Center in Cleveland, Ohio. She continues to maintain a separate clinical practice in Pittsburgh, Pennsylvania.     

Angela Wagner, M.S.  Data Analyst    

Gary Kaplan, Esq.   Legal Consultant 

Gary Kaplan is an attorney with more than 35 years experience working with companies and nonprofit organizations.  He has worked extensively with health care organizations, technology companies, emerging companies and University tech transfer offices. A graduate of Yale University and The University of Chicago Law School, Mr. Kaplan has also taught health law at Heinz College of Carnegie Mellon University and written two books and numerous articles.